Abstract
Glucocorticoids remain a valuable and necessary component of therapy for many diseases. Nonetheless, sustained glucocorticoid treatment increases potential for future cardiovascular disease through multiple pathways, resulting in a tradeoff between benefit and harm. This article explores the potential mechanisms of glucocorticoid-induced hyperglycemia and dyslipidemia. Interactions between glucocorticoids and other potential cardiovascular risk factors are also reviewed. Safe, alternate strategies for minimizing the need for glucocorticoids are urgently needed.
Copyright © 2011 Elsevier Inc. All rights reserved.
MeSH terms
-
Animals
-
Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
-
Anti-Inflammatory Agents, Non-Steroidal / adverse effects*
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
-
Blood Glucose / analysis
-
Cardiovascular Diseases / blood
-
Cardiovascular Diseases / chemically induced
-
Cardiovascular Diseases / epidemiology*
-
Diabetes Mellitus / blood
-
Diabetes Mellitus / chemically induced
-
Diabetes Mellitus / epidemiology
-
Dyslipidemias / blood
-
Dyslipidemias / chemically induced
-
Dyslipidemias / epidemiology
-
Glucocorticoids / administration & dosage
-
Glucocorticoids / adverse effects*
-
Glucocorticoids / therapeutic use
-
Humans
-
Insulin Resistance
-
Lipids / blood
-
Prevalence
-
Risk Factors
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
Blood Glucose
-
Glucocorticoids
-
Lipids